Industry Experts

Donglin Liu, Ph.D., is Founder and CEO of FrontAim Biomedicines, where he leads the development of next-generation multispecific antibody therapeutics for cancer. He previously served as Senior Scientist and Group Leader at Immunomedics, contributing to the development of antibody-based therapeutics, including programs that supported the clinical advancement of Trop-2-targeted therapies. Donglin received his Ph.D. from the Chinese Academy of Sciences and completed postdoctoral training at Rutgers University. His research focuses on innovative antibody engineering technologies that improve manufacturability, stability, and therapeutic efficacy for bispecific and multispecific antibodies targeting solid tumors and hematologic malignancies.